EPCAM and cancer: Clinical trials have demonstrated that DARPin-based radionuclide imaging probes can successfully target and visualize cancer-associated upregulation of proteins in malignancies, for example DARPin G3 targeting HER2, and Ec1 targeting EpCAM (Bragina et al. 2022; Zelchan et al. 2024).